How is Nasdaq Listing Rule 5635(c)(4) related to Ultragenyx (RARE) inducement grants?

The Ultragenyx inducement RSU grants were made in accordance with Nasdaq Listing Rule 5635(c)(4). According to Ultragenyx, the awards were structured as a material employment inducement, allowing them to be issued under the Ultragenyx Employment Inducement Plan for new hires.

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Very Positive)

Rhea-AI Summary

Ultragenyx (NASDAQ: RARE) reported an inducement equity grant under Nasdaq Listing Rule 5635(c)(4).

The company granted 17,567 restricted stock units of common stock to 11 newly hired non-executive officers on May 16, 2026, under the Ultragenyx Employment Inducement Plan. The RSUs vest over four years, in 25% annual installments.

News Market Reaction – RARE

-1.07%

-1.07% Session close to close

In the May 26 session, RARE declined 1.07%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a routine equity compensation action, granting 17,567 restricted stock uni...

Analysis

This announcement details a routine equity compensation action, granting 17,567 restricted stock units to 11 newly hired non-executive officers under Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years at 25% annually, tying retention to long-term performance. In the broader context, recent drivers for Ultragenyx have been earnings results, revenue guidance, and regulatory milestones such as UX111’s BLA acceptance, which are likely more material to the long-term equity story than this inducement grant.

Key Figures

RSU grant size: 17,567 restricted stock units Employees granted: 11 employees Vesting schedule: 4 years +1 more

4 metrics

RSU grant size 17,567 restricted stock units Inducement grant to newly hired non-executive officers

Employees granted 11 employees Newly hired non-executive officers receiving RSU awards

Vesting schedule 4 years RSUs vest in four equal annual installments

Annual vesting rate 25% per year Portion of RSUs vesting on each grant-date anniversary

Historical Context

5 past events · Latest: May 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Conference participation	Neutral	+0.8%	Announcement of participation in Bank of America 2026 healthcare conference.
May 05	Earnings and guidance	Positive	+3.7%	Q1 2026 results and reaffirmed full-year revenue guidance and profitability path.
Apr 29	Earnings call notice	Neutral	-1.4%	Scheduling of Q1 2026 results call and webcast information.
Apr 24	Inducement grant	Neutral	-0.5%	Inducement RSU grant to new non-executive officers under Nasdaq Rule 5635(c)(4).
Apr 02	Regulatory milestone	Positive	+4.8%	FDA acceptance of UX111 BLA resubmission with PDUFA date set.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news flow has been met mostly with modestly positive price reactions, especially around regulatory and earnings updates, while routine items like conference participation and inducement grants have produced limited moves.

Recent Company History

Over the last few months, Ultragenyx has combined operational updates with key regulatory and financial milestones. The company reported Q1 2026 revenue of $136M and reaffirmed $730–$760M 2026 guidance, alongside notable catalysts like FDA acceptance of the UX111 BLA with a Sep 19, 2026 PDUFA date. Routine items such as conference appearances and prior inducement grants have driven relatively small price changes. Today’s inducement grant fits into this pattern of compensation-related news with limited directional impact versus larger clinical and earnings catalysts.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), inducement plan

3 terms

restricted stock units financial

"reported the grant of 17,567 restricted stock units of the company’s common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement plan financial

"granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026"

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/22/2026 - 04:30 PM

NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 17,567 restricted stock units of the company’s common stock to 11 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

What inducement grant did Ultragenyx (NASDAQ: RARE) announce on May 22, 2026?

Ultragenyx announced an inducement grant of 17,567 restricted stock units to 11 newly hired non-executive officers. According to Ultragenyx, these RSUs were granted under the Ultragenyx Employment Inducement Plan with a grant date of May 16, 2026, subject to time-based vesting.

How many restricted stock units did Ultragenyx grant under its Employment Inducement Plan?

Ultragenyx granted 17,567 restricted stock units of its common stock as employment inducement awards. According to Ultragenyx, these RSUs were approved by the board’s compensation committee and are intended as a material inducement for new non-executive officers to join the company.

How do the Ultragenyx (RARE) inducement restricted stock units vest over four years?

The Ultragenyx inducement restricted stock units vest in four equal annual installments. According to Ultragenyx, 25% of the underlying shares vest on each anniversary of the May 16, 2026 grant date, contingent on the employee’s continuous employment at each vesting date.

Who received the Ultragenyx May 16, 2026 inducement RSU grants?

The inducement RSU grants were awarded to 11 newly hired non-executive officers at Ultragenyx. According to Ultragenyx, these grants were approved by the compensation committee as a material inducement for the new employees to enter into employment with the company.